Senti Biosciences Holdings, Inc. (SNTI)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.22
- As of
Kresmion compiles this page from SNTI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Senti Biosciences Holdings, Inc. (SNTI): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-27.
See the full SNTI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SNTI on one page. Preview it with sample data, then open it live with a free account.
Preview the SNTI dossierActive events for SNTI
- mediumEarnings below estimates
Q2-2026: Missed consensus by 51.7%, EPS $-0.41 vs $-0.2703 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 39.0% - EPS $-0.56 vs $-0.918 estimate
- mediumEarnings below estimates
Q3-2025: Missed consensus by 19.4% - EPS $-0.69 vs $-0.578 estimate
- mediumEarnings above estimates
Beat consensus by 39.0% - EPS $-0.56 vs $-0.918 estimate
- mediumEarnings below estimates
Missed consensus by 19.4% - EPS $-0.69 vs $-0.578 estimate
FREE, NO ACCOUNT
Every event on SNTI, as it fires
You are seeing 5 of 6 events recorded on SNTI since 2026-06-03.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SNTI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 816944102 · 2026Q2 | $118K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SNTI
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SNTI against its peers
SNTI's operating margin of -312631.8% ranks in the 5th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-08-31 and 2026-04-30.
| Metric | SNTI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 22000 USD | 418189 USD | 30 | 14 |
| Gross margin | n/a | 35.3% | n/a | 7 |
| Operating margin | -312631.8% | -1812.6% | 5 | 10 |
| Net margin | -279263.6% | -1686.0% | 4 | 11 |
| Return on equity | -1099.3% | -207.3% | 8 | 18 |
Peers (21): ACXP, RVPH, BGMS, TRAW, SNGX, LGVN, CELZ, AZTR, ALZN, SKYE, PCSA, CSCIF, NIKI, PULM, VSBC, CANF, APRE, AIM, LEXX, IMNN, EVGN. Left out: LIANY (no annual filing), ADXN (period gap), ENVB (no annual filing), FBLG (no annual filing). Fiscal periods ending between 2025-08-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (SNTI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SNTI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SNTI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.